142 related articles for article (PubMed ID: 26378035)
1. Using Whole-Exome Sequencing to Identify Genetic Markers for Carboplatin and Gemcitabine-Induced Toxicities.
Gréen H; Hasmats J; Kupershmidt I; Edsgärd D; de Petris L; Lewensohn R; Blackhall F; Vikingsson S; Besse B; Lindgren A; Brandén E; Koyi H; Peterson C; Lundeberg J
Clin Cancer Res; 2016 Jan; 22(2):366-73. PubMed ID: 26378035
[TBL] [Abstract][Full Text] [Related]
2. Genes and variants in hematopoiesis-related pathways are associated with gemcitabine/carboplatin-induced thrombocytopenia.
Björn N; Sigurgeirsson B; Svedberg A; Pradhananga S; Brandén E; Koyi H; Lewensohn R; de Petris L; Apellániz-Ruiz M; Rodríguez-Antona C; Lundeberg J; Gréen H
Pharmacogenomics J; 2020 Apr; 20(2):179-191. PubMed ID: 31616045
[TBL] [Abstract][Full Text] [Related]
3. Genetic association of gemcitabine/carboplatin-induced leukopenia and neutropenia in non-small cell lung cancer patients using whole-exome sequencing.
Svedberg A; Björn N; Sigurgeirsson B; Pradhananga S; Brandén E; Koyi H; Lewensohn R; De Petris L; Apellániz-Ruiz M; Rodríguez-Antona C; Lundeberg J; Gréen H
Lung Cancer; 2020 Sep; 147():106-114. PubMed ID: 32683206
[TBL] [Abstract][Full Text] [Related]
4. Whole-genome sequencing and gene network modules predict gemcitabine/carboplatin-induced myelosuppression in non-small cell lung cancer patients.
Björn N; Badam TVS; Spalinskas R; Brandén E; Koyi H; Lewensohn R; De Petris L; Lubovac-Pilav Z; Sahlén P; Lundeberg J; Gustafsson M; Gréen H
NPJ Syst Biol Appl; 2020 Aug; 6(1):25. PubMed ID: 32839457
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced nonsmall cell lung carcinoma.
Hainsworth JD; Burris HA; Erland JB; Morrissey LH; Meluch AA; Kalman LA; Hon JK; Scullin DC; Smith SW; Greco FA
Cancer; 1999 Mar; 85(6):1269-76. PubMed ID: 10189131
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of gemcitabine and carboplatin in advanced non-small cell lung carcinoma.
Gajra A; Mehdi SA; Kirshner J; Newman N; Graziano SL
Lung Cancer; 2001 May; 32(2):189-96. PubMed ID: 11325490
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of carboplatin plus gemcitabine in advanced non-small-cell lung cancer (NSCLC): a hoosier oncology group study.
Ng EW; Sandler AB; Robinson L; Einhorn LH
Am J Clin Oncol; 1999 Dec; 22(6):550-3. PubMed ID: 10597737
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of gemcitabine and carboplatin in metastatic non-small-cell lung cancer: a Groupe Français de Pneumo-Cancérologie Study.
Thomas P; Robinet G; Ferri-Dessens RM; Léna H; Gouva S; Vernejoux JM; Kleisbauer JP
Lung Cancer; 2002 May; 36(2):191-8. PubMed ID: 11955654
[TBL] [Abstract][Full Text] [Related]
9. The association of four genetic variants with myelosuppression in gemcitabine-treated Japanese is not evident in gemcitabine/carboplatin-treated Swedes.
Björn N; Jakobsen I; Udagawa C; Brandén E; Koyi H; Lewensohn R; De Petris L; Zembutsu H; Gréen H
Basic Clin Pharmacol Toxicol; 2022 Apr; 130(4):513-521. PubMed ID: 35132780
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase II study of two schedules of carboplatin and gemcitabine for stage IIIB and IV advanced non-small cell lung cancer (JACCRO LC-01 study).
Imamura F; Nishio M; Noro R; Tsuboi M; Ikeda N; Inoue A; Ohsaki Y; Kimura Y; Nishino K; Uchida J; Horai T
Chemotherapy; 2011; 57(4):357-62. PubMed ID: 21912118
[TBL] [Abstract][Full Text] [Related]
11. Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer.
Iaffaioli RV; Tortoriello A; Facchini G; Caponigro F; Gentile M; Marzano N; Gravina A; Dimitri P; Costagliola G; Ferraro A; Ferrante G; De Marino V; Illiano A
J Clin Oncol; 1999 Mar; 17(3):921-6. PubMed ID: 10071285
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of gemcitabine and carboplatin in non-small cell lung cancer.
Carmichael J; Allerheiligen S; Walling J
Semin Oncol; 1996 Oct; 23(5 Suppl 10):55-9. PubMed ID: 8893883
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer.
Wang LR; Huang MZ; Zhang GB; Xu N; Wu XH
Cancer Chemother Pharmacol; 2007 Sep; 60(4):601-7. PubMed ID: 17549479
[TBL] [Abstract][Full Text] [Related]
14. Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
Gray HJ; Bell-McGuinn K; Fleming GF; Cristea M; Xiong H; Sullivan D; Luo Y; McKee MD; Munasinghe W; Martin LP
Gynecol Oncol; 2018 Mar; 148(3):507-514. PubMed ID: 29352572
[TBL] [Abstract][Full Text] [Related]
15. Combination of low-dose gemcitabine in 6-hour infusion and carboplatin is a favorable option for patients in poor performance status with advanced non-small cell lung cancer.
Wu ZY; Guan HH; Lin ZX; Yang HK; Zhou L; Cai QC
J Chemother; 2014 Oct; 26(5):306-11. PubMed ID: 24075685
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine and low dose carboplatin in the treatment of elderly patients with advanced non-small cell lung cancer.
Maestu I; Gómez-Aldaraví L; Torregrosa MD; Camps C; Llorca C; Bosch C; Gómez J; Giner V; Oltra A; Albert A
Lung Cancer; 2003 Dec; 42(3):345-54. PubMed ID: 14644523
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated.
Chen YM; Perng RP; Lee YC; Shih JF; Lee CS; Tsai CM; Whang-Peng J
Ann Oncol; 2002 Jan; 13(1):108-15. PubMed ID: 11863090
[TBL] [Abstract][Full Text] [Related]
18. Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial.
Tan AR; Wright GS; Thummala AR; Danso MA; Popovic L; Pluard TJ; Han HS; Vojnović Ž; Vasev N; Ma L; Richards DA; Wilks ST; Milenković D; Yang Z; Antal JM; Morris SR; O'Shaughnessy J
Lancet Oncol; 2019 Nov; 20(11):1587-1601. PubMed ID: 31575503
[TBL] [Abstract][Full Text] [Related]
19. [Phase II study of combination of gemcitabine and carboplatin in advanced non-small cell lung cancer (an interim report)].
Mori K; Kamiyama Y; Kondoh T; Kodama T
Gan To Kagaku Ryoho; 2008 Jun; 35(6):931-5. PubMed ID: 18633219
[TBL] [Abstract][Full Text] [Related]
20. The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.
Davies AM; Ruel C; Lara PN; Lau DH; Gumerlock PH; Bold R; Shibata S; Lenz HJ; Schenkein DP; Gandara DR
J Thorac Oncol; 2008 Jan; 3(1):68-74. PubMed ID: 18166843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
